

Jay S Epstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8279336/publications.pdf>

Version: 2024-02-01

76
papers

2,091
citations

304743

22
h-index

243625

44
g-index

79
all docs

79
docs citations

79
times ranked

1609
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. <i>Transfusion</i> , 2003, 43, 788-798.	1.6	241
2	Bacterial Contamination of Blood Components: Risks, Strategies, and Regulation. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 575-589.	2.5	221
3	Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. <i>Transfusion</i> , 1986, 26, 210-213.	1.6	153
4	Prevalence of Human Immunodeficiency Virus Type 1 p24 Antigen in U.S. Blood Donors – An Assessment of the Efficacy of Testing in Donor Screening. <i>New England Journal of Medicine</i> , 1990, 323, 1312-1317.	27.0	130
5	Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. <i>Transfusion</i> , 2012, 52, 2113-2121.	1.6	77
6	CONFERENCE REPORT: Transfusion-transmitted babesiosis in the United States: summary of a workshop. <i>Transfusion</i> , 2009, 49, 2759-2771.	1.6	75
7	Screening of Blood Donations for Zika Virus Infection – Puerto Rico, April 3–June 11, 2016. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 627-628.	15.1	75
8	Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. <i>Vox Sanguinis</i> , 2020, 115, 485-487.	1.5	73
9	Crisis in the Sustainability of the U.S. Blood System. <i>New England Journal of Medicine</i> , 2017, 377, 1485-1488.	27.0	67
10	A novel method employing UNG to avoid carry-over contamination in RNA-PCR. <i>Nucleic Acids Research</i> , 1993, 21, 3917-3918.	14.5	57
11	Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation. <i>Transfusion</i> , 1986, 26, 481-483.	1.6	56
12	Problem Solved? West Nile Virus and Transfusion Safety. <i>New England Journal of Medicine</i> , 2005, 353, 516-517.	27.0	56
13	NAT screening of blood and plasma donations: evolution of technology and regulatory policy*. <i>Transfusion</i> , 2002, 42, 1230-1237.	1.6	51
14	FDA approach to evaluation of pathogen reduction technology. <i>Transfusion</i> , 2003, 43, 1347-1350.	1.6	43
15	Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. <i>Transfusion</i> , 2009, 49, 1102-1114.	1.6	39
16	Public health service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. <i>American Journal of Infection Control</i> , 1991, 19, 32A-41A.	2.3	38
17	Interferon- γ -Induced Downregulation of CD4 Inhibits the Entry of Human Immunodeficiency Virus Type-1 in Primary Monocytes. <i>Pathobiology</i> , 1995, 63, 93-99.	3.8	32
18	Chikungunya virus: new risk to transfusion safety in the Americas. <i>Transfusion</i> , 2014, 54, 1911-1915.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. <i>Antiviral Research</i> , 1996, 33, 11-20.	4.1	27
20	Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. <i>Clinical and Diagnostic Virology</i> , 1996, 7, 85-92.	1.7	26
21	Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR. , 1997, 52, 179-189.		25
22	Alternative strategies in assuring blood safety: An Overview. <i>Biologicals</i> , 2010, 38, 31-35.	1.4	25
23	PREVALENCE, CLINICAL MANIFESTATIONS, AND IMMUNOLOGY OF HERPESVIRUS INFECTIONS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME. <i>Annals of the New York Academy of Sciences</i> , 1984, 437, 200-205.	3.8	23
24	Inhibition of HIV-1 Replication in H9 Cells by Nystatin-A Compared with Other Antiviral Agents. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 475-481.	1.1	22
25	Chemokine receptors and HIV-2. <i>Aids</i> , 1997, 11, 1198-1199.	2.2	22
26	Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. <i>Vox Sanguinis</i> , 2021, 116, 13-14.	1.5	22
27	Interferon- β inhibits HIV-induced invasiveness of monocytes. <i>Journal of Leukocyte Biology</i> , 1995, 58, 713-716.	3.3	20
28	Risk assessment for transmission of variant Creutzfeldt-Jakob disease by transfusion of red blood cells in the United States. <i>Transfusion</i> , 2014, 54, 2194-2201.	1.6	18
29	Oversight and Monitoring of Blood Safety in the United States. <i>Vox Sanguinis</i> , 1999, 77, 67-76.	1.5	17
30	Role of regulatory agencies. <i>Biologicals</i> , 2009, 37, 94-102.	1.4	15
31	Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. <i>Journal of Virological Methods</i> , 1994, 49, 37-46.	2.1	14
32	POTENTIAL USE OF THE SCAN STATISTIC FOR QUALITY CONTROL IN BLOOD PRODUCT MANUFACTURING. <i>Journal of Biopharmaceutical Statistics</i> , 2005, 15, 353-366.	0.8	14
33	Best practices in regulation of blood and blood products. <i>Biologicals</i> , 2012, 40, 200-204.	1.4	14
34	Blood system changes since recognition of transfusion-associated AIDS. <i>Transfusion</i> , 2013, 53, 2365-2374.	1.6	14
35	Crisis in the Sustainability of the U.S. Blood System. <i>New England Journal of Medicine</i> , 2018, 378, 305-306.	27.0	14
36	Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 1057-1057.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop. <i>Transfusion</i> , 2013, 53, 455-463.	1.6	12
38	Maintaining a Safe Blood Supply in an Era of Emerging Pathogens. <i>Journal of Infectious Diseases</i> , 2016, 213, 1676-1677.	4.0	12
39	9-Nitrocamptothecin Inhibits Tumor Necrosis Factor-Mediated Activation of Human Immunodeficiency Virus Type 1 and Enhances Apoptosis in a Latently Infected T Cell Clone. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 39-49.	1.1	11
40	Nationwide Outbreak of Red Eye Syndrome Associated With Transfusion of Leukocyte-Reduced Red Blood Cell Units. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 1146-1152.	1.8	11
41	Insights on donor screening for West Nile virus. <i>Transfusion</i> , 2005, 45, 460-462.	1.6	10
42	Evidence of HIV-2 Infection in Equatorial Guinea (Central Africa): Partial Genetic Analysis of a B Subtype Virus. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 439-440.	1.1	9
43	Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425.	0.3	9
44	Hepatitis C virus lookback: emerging science and public policy. <i>Transfusion</i> , 2000, 40, 3-5.	1.6	8
45	Prevention of herpes simplex virus diseases in man. <i>Clinics in Dermatology</i> , 1984, 2, 133-146.	1.6	7
46	Impaired antigen presentation to CD4+ T-cells by HIV-infected monocytes is related to down-modulation of CD4 expression on helper T-cells: Possible involvement of HIV-induced cellular factors. <i>FEBS Letters</i> , 1996, 398, 1-6.	2.8	7
47	Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefield. <i>Transfusion</i> , 2016, 56, 1669-1672.	1.6	7
48	Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop. <i>Vox Sanguinis</i> , 2022, 117, 789-795.	1.5	7
49	Management of severe VWD with cryoprecipitate collected by repeated apheresis of a single dedicated donor. <i>Transfusion</i> , 2003, 43, 1514-1521.	1.6	6
50	Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?. <i>Transfusion</i> , 2015, 55, S122-6.	1.6	6
51	Studies on the Antioxidant Action of Thyroxine and Related Compounds. <i>Journal of Medicinal Chemistry</i> , 1967, 10, 1081-1085.	6.4	5
52	Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900.	1.1	5
53	Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473.	1.1	5
54	Hemolytic adverse events with immune globulin products: product factors and patient risks. <i>Transfusion</i> , 2015, 55, S2-5.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Idiopathic CD4+ T Lymphocytopenia: A Review and Current Perspective. <i>Transfusion Medicine Reviews</i> , 1994, 8, 223-231.	2.0	4
56	Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome. <i>Aids</i> , 1994, 8, 267.	2.2	4
57	Important drug information: Immune globulin intravenous (human). <i>Disaster Management and Response</i> , 1999, 5, 139-140.	0.1	4
58	Improving haemophilia therapy in developing countries: virus-safe cryoprecipitate. <i>Vox Sanguinis</i> , 2019, 114, 635-636.	1.5	4
59	Interaction Between Cu(II) and Thyroxine-like Compounds in Mitochondrial Swelling Studies. <i>Endocrinology</i> , 1967, 81, 291-298.	2.8	3
60	Summary of a Food and Drug Administration workshop on nucleic acid testing to screen donations of blood and plasma for the hepatitis C virus. <i>Transfusion</i> , 1999, 39, 912-913.	1.6	3
61	Recovered plasma for fractionation: call for quality standards to end wastage. <i>Vox Sanguinis</i> , 2020, 115, 213-214.	1.5	3
62	Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections. <i>Npj Vaccines</i> , 2020, 5, 103.	6.0	3
63	A WHO tool for risk-based decision making on blood safety interventions. <i>Transfusion</i> , 2021, 61, 503-515.	1.6	3
64	An anti-p24 monoclonal antibody shows cross-reactivity with multiple HIV-1 proteins. <i>Journal of Immunological Methods</i> , 1990, 132, 57-62.	1.4	2
65	Sensitivity and consistency of screening tests for antibodies to human immunodeficiency virus type 1. <i>Transfusion</i> , 1991, 31, 388-389.	1.6	2
66	Significance of Positive Polymerase Chain Reaction Results in HIV-Seronegative Individuals. <i>Vox Sanguinis</i> , 1992, 63, 287-288.	1.5	2
67	A novel, sensitive radioimmunoprecipitation assay for the detection of antibodies to human immunodeficiency virus-type 2. <i>Journal of Virological Methods</i> , 1993, 44, 1-10.	2.1	2
68	Sequence Note : Genetic Analysis of Human Immunodeficiency Virus Type 2 Strains from Spain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 91-94.	1.1	2
69	Detection of acquired B antigen by monoclonal anti-B blood grouping reagents. <i>Transfusion</i> , 1997, 37, 103-105.	1.6	1
70	FDA contributions to reduction of bacterial contamination in platelet products within the United States. <i>Transfusion</i> , 2013, 53, 232-233.	1.6	1
71	Serotherapy for patients with severe influenza. <i>Lancet Respiratory Medicine</i> , 2017, 5, 462-464.	10.7	1
72	Use of multiple immunoassay systems to determine antibodies directed against the human immunodeficiency virus. <i>Transfusion</i> , 1987, 27, 1-1.	1.6	0

#	ARTICLE	IF	CITATIONS
73	A Rapid, Sensitive, PCR-Based Method for Detection of HIV-1 Specific Nucleic Acid in the Culture Supernatant of Infected Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 264-267.	3.8	0
74	Evaluation of Anti-HIV Agents in Vitro by Quantitative PCR. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 306-308.	3.8	0
75	Blood safety: Opportunities and challenges addressed through Critical Path research at FDA. <i>Drug Discovery Today: Technologies</i> , 2007, 4, 51-54.	4.0	0
76	The Role of the Food and Drug Administration in Development and Standardization of Tests for HIV and HTLV-I. <i>Infection Control and Hospital Epidemiology</i> , 1988, 9, 362-362.	1.8	0